Published in:
Open Access 01-10-2019 | Idiopathic Pulmonary Fibrosis | Correction
Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Published in: Advances in Therapy | Issue 10/2019
Login to get accessExcerpt
In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given below
Fig. 2
Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)
× ![]()
…